产品
编 号：F117009
分子式：C21H13ClF3N3O2
分子量：431.8
分子式：C21H13ClF3N3O2
分子量：431.8
产品类型
规格
价格
是否有货
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
25mg
询价
询价
结构图
CAS No: 1313019-65-6
产品详情
生物活性：
STAT3-IN-7 is a Sorafenib analogue and potently inhibits the phosphorylation of STAT3. STAT3-IN-7 induces cell apoptosis through SHP-1 dependent STAT3 inactivation. STAT3-IN-7 does not inhibit kinase activity and has anticancer effects.
体内研究：
STAT3-IN-7 (10 mg/kg; oral gavage; daily; for 28 days; female NCr athymic nude mice) treatment shows efficacious antitumor activity and p-STAT3 downregulation in MDA-MB-468 xenograft tumors.Animal Model:Female NCr athymic nude mice (4-6 weeks of age) injected with breast cancer cells
Dosage:10 mg/kg
Administration:Oral gavage; daily; for 28 days
Result:Showed efficacious antitumor activity and p-STAT3 downregulation in MDA-MB-468 xenograft tumors.
体外研究：
STAT3-IN-7 (SC-1; 1-10 μM; 48 hours; breast cancer cells) treatment demonstrates dose-dependent suppression of cell viability in all tested breast cancer cells.STAT3-IN-7 (SC-1; 1-10 μM; 36 hours; breast cancer cells) treatment induces potent apoptotic activity.STAT3-IN-7 (SC-1; 1-10 μM; 36 hours; breast cancer cells) treatment shows downregulation of p-STAT3 and its downstream proteins cyclin D1 and survivin in a dose-dependent manner in breast cancer cell lines.
STAT3-IN-7 is a Sorafenib analogue and potently inhibits the phosphorylation of STAT3. STAT3-IN-7 induces cell apoptosis through SHP-1 dependent STAT3 inactivation. STAT3-IN-7 does not inhibit kinase activity and has anticancer effects.
体内研究：
STAT3-IN-7 (10 mg/kg; oral gavage; daily; for 28 days; female NCr athymic nude mice) treatment shows efficacious antitumor activity and p-STAT3 downregulation in MDA-MB-468 xenograft tumors.Animal Model:Female NCr athymic nude mice (4-6 weeks of age) injected with breast cancer cells
Dosage:10 mg/kg
Administration:Oral gavage; daily; for 28 days
Result:Showed efficacious antitumor activity and p-STAT3 downregulation in MDA-MB-468 xenograft tumors.
体外研究：
STAT3-IN-7 (SC-1; 1-10 μM; 48 hours; breast cancer cells) treatment demonstrates dose-dependent suppression of cell viability in all tested breast cancer cells.STAT3-IN-7 (SC-1; 1-10 μM; 36 hours; breast cancer cells) treatment induces potent apoptotic activity.STAT3-IN-7 (SC-1; 1-10 μM; 36 hours; breast cancer cells) treatment shows downregulation of p-STAT3 and its downstream proteins cyclin D1 and survivin in a dose-dependent manner in breast cancer cell lines.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备